Investor 'Hand-Wringing' Continues As Tiny Biotech Takes On Pfizer [Investor's Business Daily]
Deciphera Pharmaceuticals, Inc. (DCPH)
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
deciphera.com/investor-relations
Company Research
Source: Investors Business Daily
Related news Deciphera Pharmaceuticals ( DCPH ) toppled Friday on mixed data for its stomach cancer treatment, though an analyst still expects the experimental medication to beat out a blockbuster from Pfizer ( PFE ). In morning trading on the stock market today , Deciphera stock slipped 7.9%, near 25.10, after earlier falling as much as 12.6% in higher-than-average volume . Pfizer stock lifted 1.6%, near 44.70. Meanwhile, shares of rival Blueprint Medicines ( BPMC ) rose 0.9%, near 70.30. The biotech updated results for its stomach cancer treatment, DCC-2618. Investors focused on patients taking the drug as a second treatment. The data appeared to stack up well against Pfizer's drug, Sutent. But objective responses in that group declined from a release in June . Piper Jaffray analyst Christopher Raymond was encouraged by the Sutent comparison. He noted that another patient responded just after the cutoff, which raises the objective response rate. That patient's response has yet to b
Show less
Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCPH alerts
High impacting Deciphera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
DCPH
News
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)PR Newswire
- Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumBusiness Wire
- Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors [Yahoo! Finance]Yahoo! Finance
DCPH
Earnings
- 2/6/24 - Beat
DCPH
Sec Filings
- 4/22/24 - Form PRER14A
- 4/11/24 - Form PRE
- 2/20/24 - Form 4
- DCPH's page on the SEC website